Sunday, February 8, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home ETF

A Deep Dive into the iShares MSCI EAFE ETF’s Market-Leading Performance

Andreas Sommer by Andreas Sommer
January 16, 2026
in ETF, European Markets, Market Commentary, Value & Growth
0
iShares MSCI EAFE ETF Stock
0
SHARES
17
VIEWS
Share on FacebookShare on Twitter

International equities, as represented by the iShares MSCI EAFE ETF (ticker: EFA), have delivered a standout performance. This fund provides diversified exposure to developed markets outside the United States and Canada. In a notable shift, the MSCI EAFE index surged 31.2% throughout 2025, significantly outpacing the S&P 500’s 17.9% gain. This raises a pivotal question for investors: can this divergence from U.S. market performance be sustained?

Key Fund Metrics
* Assets Under Management: $72.92 billion
* Expense Ratio: 0.32%
* Replication Method & Distribution: Physical replication with semi-annual dividends
* Major Country Allocations: Japan (22.16%), United Kingdom (14.63%), France (10.84%)
* Performance Data (Mid-January 2026): 1-year return of +37.53%; year-to-date return of +2.81%

Composition and Sector Exposure

The ETF’s portfolio contains more than 700 large- and mid-capitalization stocks. Its top ten holdings, which include industry leaders like ASML, Roche, and AstraZeneca, constitute approximately 13.3% of total assets, preventing any single security from dominating. The fund’s sector allocation reveals a significant tilt toward Financials, which account for 24.9% of the portfolio. Industrials (19.6%) and Health Care (11.4%) represent the next largest sector weights. This broad diversification across both nations and industries is designed to mitigate country-specific economic risks.

Trading Dynamics and Recent Returns

EFA demonstrates high liquidity, with average daily volume reaching 15–20 million shares in early January and a typical bid-ask spread of around 0.01%. As of January 15, 2026, the ETF traded at a modest 0.03% premium to its Net Asset Value (NAV) of $99.17. Its one-year median premium has historically been near 0.06%, indicating efficient tracking of the underlying index. The fund has also shown strong recent momentum, posting gains of 8.78% over three months and 5.41% over one month.

Should investors sell immediately? Or is it worth buying iShares MSCI EAFE ETF?

Competitive Landscape and Forward Drivers

Investors evaluating EFA must consider lower-cost alternatives in the same category. Competing funds include the iShares Core MSCI EAFE ETF (IEFA) with a 0.07% expense ratio and roughly $169.9 billion in AUM, and the Vanguard FTSE Developed Markets ETF (VEA), which charges 0.03% and manages approximately $200.8 billion. While EFA boasts a long track record and excellent liquidity, its higher fee structure presents a headwind to net returns compared to these core, index-tracking products.

Several concrete factors will influence the fund’s trajectory in the coming months. The semi-annual index rebalancing, with the next scheduled for May, is a key event. Macroeconomic conditions also play a crucial role, notably the U.S. dollar’s 9.4% depreciation in 2025, which provided a tailwind for foreign asset returns. Thematic trends such as widespread AI adoption and rising defense budgets may continue to support technology and industrial constituents. Furthermore, an anticipated easing of restrictive U.S. monetary policy in 2026 is expected to influence currency dynamics, a critical component of returns for U.S.-based investors in international funds like EFA.

Until the May rebalancing, currency fluctuations and the performance of core sectors—including semiconductor equipment, pharmaceuticals, and industrials—will likely dictate the ETF’s short- to medium-term direction.

Ad

iShares MSCI EAFE ETF Stock: Buy or Sell?! New iShares MSCI EAFE ETF Analysis from February 8 delivers the answer:

The latest iShares MSCI EAFE ETF figures speak for themselves: Urgent action needed for iShares MSCI EAFE ETF investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 8.

iShares MSCI EAFE ETF: Buy or sell? Read more here...

Tags: iShares MSCI EAFE ETF
Andreas Sommer

Andreas Sommer

About Andreas Sommer Over 40 years of expertise in market analysis, chart technical analysis, and strategic investment advisory. With more than four decades of experience in banking and financial journalism, Andreas Sommer is recognized as one of the leading analysts in the German-speaking market. His deep understanding of market dynamics and technical analysis has helped countless investors navigate complex financial markets.
Areas of Expertise:
  • Technical Chart Analysis
  • Strategic Investment Advisory
  • Market Trend Analysis
  • Financial Journalism
Andreas brings unparalleled insights from his extensive career in banking and financial markets, making him a trusted voice for investors seeking professional guidance.

Related Posts

Repay Holdings Stock
Analysis

Repay Holdings: Annual Report to Test Strategic Refinancing Success

February 7, 2026
Communications Stock
Industrial

The Race to Rewire: Fiber Optics Reshape the Telecom Landscape

February 7, 2026
Boston Omaha Stock
Analysis

Investors Await March Report for Boston Omaha’s Strategic Direction

February 7, 2026
Next Post
Microchip Stock

Microchip Shares Gain Momentum on Upbeat Forecast

DeFi Technologies Stock

Legal Challenges Mount for DeFi Technologies Shareholders

Voestalpine Stock

Voestalpine Shares Slip Despite Securing Historic Contract

Recommended

Biotechnology Stock Exchange

Analysts Bullish on Dynatrace with Price Targets on the Rise

2 years ago
The Trade Desk Stock

The Trade Desk Faces Mounting Pressure as Amazon Strikes Netflix Deal

5 months ago

Analyst Reaffirms Buy Rating on International Seaways with 66 Price Target

2 years ago
Biotechnology Stock Bull Market

KeyBanc Analyst Raises Price Target and Maintains Overweight Rating on Repligen NASDAQ RGEN

2 years ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy

Repay Holdings: Annual Report to Test Strategic Refinancing Success

Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

Graftech Shares Plunge on Bleak Quarterly Results

Potbelly Accelerates Northeast Growth with New Jersey Franchise Push

Conduent Faces Mounting Fallout from Major Data Breach Ahead of Earnings

Trending

Puma Biotechnology Stock
Earnings

Puma Biotechnology Sets Date for Full-Year Financial Disclosure

by Jackson Burston
February 8, 2026
0

Investor attention is now firmly fixed on February 26, 2026, as Puma Biotechnology prepares to release its...

Quanterix Stock

Quanterix Seeks FDA Clearance for Groundbreaking Alzheimer’s Blood Test

February 8, 2026
Design Therapeutics Stock

Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

February 7, 2026
Vigil Neuroscience Stock

Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy

February 7, 2026
Repay Holdings Stock

Repay Holdings: Annual Report to Test Strategic Refinancing Success

February 7, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Puma Biotechnology Sets Date for Full-Year Financial Disclosure
  • Quanterix Seeks FDA Clearance for Groundbreaking Alzheimer’s Blood Test
  • Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com